Epstein-Barr virus, rapamycin, and host immune responses

Area of Science:

• Immunology
• Virology
• Oncology

Background:

• Epstein-Barr virus (EBV) poses a significant risk for posttransplant lymphoproliferative disease (PTLD) in transplant recipients.
• Understanding EBV's pathobiology and host immune interactions is crucial for managing PTLD.
• EBV-associated B-cell lymphomas are a major concern in immunocompromised individuals.

Purpose of the Study:

• To review recent advancements in EBV-associated PTLD.
• To explore the host immune response to EBV-infected B cells.
• To elucidate the molecular mechanisms of mammalian target of rapamycin (mTOR) inhibitors in EBV+ B-cell lymphomas.

Main Methods:

• Review of current literature on EBV-associated PTLD.
• Analysis of cytogenetic and genomic data.
• Examination of host immune responses, including T-cell function.
• Investigation of signaling pathways, such as the PI3K/Akt/mTOR pathway.

Main Results:

• EBV-associated PTLD exhibits complex underlying biology.
• Transplant recipients may have impaired EBV-specific CD8+ memory T-cell function.
• EBV employs diverse strategies to evade host immune surveillance.
• The PI3K/Akt/mTOR pathway is critical for PTLD-associated EBV+ B-cell lymphoma growth and survival.

Conclusions:

• PTLD development is multifactorial, influenced by host immunity, viral factors, and immunosuppression.
• Effective management requires understanding the interplay between the host, virus, and therapeutic interventions.
• Targeting key signaling pathways may offer therapeutic strategies for EBV+ lymphomas.